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Neurons and glia are thought to arise from multipotent and
self-renewing stem cells, which comprise the majority of neuro-
epithelial cells in the ventricular zone (VZ) of the early embryonic
CNS. However, this idea remains to be tested rigorously, because
CNS stem cells have been identified only by using in vitro assays,
from which their abundance in vivo cannot be directly inferred. In
the hematopoietic system, stem cells are characterized by using
prospective isolation and direct in vivo transplantation. Here we
have used this approach to ask whether most VZ progenitors
behave as stem cells in vivo. The best-studied region of the
embryonic CNS for addressing this problem is, arguably, the
ventral spinal cord, within which progenitors in the motoneuron
progenitor (pMN) domain sequentially generate motoneurons
(MNs) and oligodendrocyte precursors (OPs). Virtually all VZ cells in
pMN express the transcription factor Olig2. If most of these cells
are stem cells, then they should maintain neurogenic potential,
even at later, gliogenic stages. To test this hypothesis, we have
prospectively isolated Olig2 cells from murine embryonic day
(E)9.5 and E13.5 spinal cord and directly transplanted them to E2
chick spinal cord. Transplanted E9.5 cells generate both neurons,
including MNs and OPs, whereas E13.5 cells generate. The obser-
vation that most Olig2 progenitors do not maintain neurogenic
potential into the period of gliogenesis argues that they do not
self-renew. These results do not support the commonly held view
that most neuroepithelial cells in the embryonic CNS VZ are stem
cells in vivo.
CNS stem cells  neuroepithelial cells  in vivo transplantation
S tem cells are defined as undifferentiated progenitors that canself-renew and give rise to one or more differentiated
derivatives. The multipotency and self-renewal of hematopoietic
stem cells (HSCs) have been established by using direct in vivo
transplantation of prospectively isolated progenitor cells (1). In
contrast, the multipotency and self-renewal of stem cells in the
CNS have been established primarily by using in vitro assays
(reviewed in refs. 2 and 3). Such experiments have led to an
operational definition of CNS stem cells (CNS-SCs) as self-
renewing, clonogenic progenitors of neurons and glia (4). These
cells can be passaged over many generations, in the presence of
high concentrations of mitogens such as FGF-2, while retaining
multipotency (5–7). Because these cells express markers, such as
nestin (8, 9), that are expressed by most or all neuroepithelial
cells in the embryonic ventricular zone (VZ), it has been inferred
that most neuroepithelial cells (or, at later stages, radial glial
cells) are multipotent stem cells in vivo (10–14). However,
because evidence increasingly suggests that the culture condi-
tions used to grow CNS progenitors in vitro may alter their
developmental properties (15–17), it has become important to
directly test this inference, without resorting to in vitro assays.
Here, we have asked whether most neuroepithelial cells are
multipotent and self-renewing in vivo by direct transplantation of
a population of candidate stem cells isolated from a well defined
domain of the embryonic VZ. The best studied region of the
embryonic CNS for addressing this questions is, arguably, the
ventral spinal cord, where progenitors expressing the transcrip-
tion factor Olig2 (18–20) sequentially generate motoneurons
(MNs) and oligodendrocyte precursors (OPs) (reviewed in refs.
21 and 22). Single Olig2 cells can form multipotent, self-
renewing neurospheres (17) and, therefore, can behave as stem
cells in vitro. Self-renewal of CNS-SCs is defined as the main-
tenance of neuronal and glial potential over multiple genera-
tions. According to this definition, if most Olig2 progenitors
self-renew in vivo, then they should retain neuronal potential,
even at stages when they are fated to generate only OPs. But if
Olig2 cells do not maintain neuronal potential at later, glio-
genic stages, then it follows that they do not self-renew.
To distinguish between these alternatives, we prospectively
isolated Olig2 cells at different stages and directly transplanted
them into chick embryonic spinal cord, at a stage permissive for
MN differentiation (Fig. 1A). Such a transplantation assay
should reveal whether Olig2 cells retain neuronal potential at
a stage when they are fated to generate only OPs in vivo. We find
that Olig2 cells isolated at embryonic day 13.5 (E13.5) generate
only glial derivatives after transplantation. By contrast, Olig2
cells from E9.5 embryos readily generate MNs in the same assay.
Thus, most Olig2 cells do not maintain neuronal capacity and,
therefore, do not self-renew. Because essentially all VZ cells in
the MN progenitor domain at E9.5 express Olig2, these results
argue against the commonly held view that most CNS neuroep-
ithelial cells are stem cells in vivo.
Results
Olig2-Expressing Cells Are Candidate Stem Cells in the Embryonic
Spinal Cord. To investigate whether Olig2 cells are candidate
stem cells in the MN progenitor (pMN) domain, we first
determined their abundance in the VZ and their expression of
CNS-SC markers. At E9.5, when VZ cells in the pMN domain
are generating MNs, the vast majority (99.9%) of these cells in
situ express Olig2, as determined by quantification of triply
immunostained sections (Fig. 1B; 3,554 Olig2 cells3,558
DAPI, Irx3/low, Nkx2.2/low cells, n  2 embryos counted).
The majority of these cells coexpress the CNS-SC markers Sox2
(23) (98  1%), nestin (9) (92  6%), and CD133 (24) (97 
2%), and the proliferation marker PCNA and lack expression of
markers of differentiated neurons or OPs (NeuN or PDGFR,
respectively; see Fig. 6 and Table 2, which are published as
supporting information on the PNAS web site). Similarly, at
E13.5, when MN generation has ceased and OPs are being
generated, Olig2 cells comprise 99% (99.37  0.37%, n 
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1,068 cells counted in two embryos) of VZ cells between the
domain bounded dorsally by Pax6 and that bounded ventrally by
Nkx2.2. These Olig2 cells coexpressed CNS-SC markers, such
as Sox2, nestin, and RC2, a marker of radial glia (12, 13) (see Fig.
7 and Table 2, which are published as supporting information on
the PNAS web site).
In the hematopoietic system, stem and progenitor cells are
prospectively isolated by using surface markers. In contrast,
Olig2 is a nuclear protein. However, Olig2 cells can be isolated
from murine embryos expressing GFP from the Olig2 locus (ref.
17 and B.G.N. and T.M.J., unpublished work). To further enrich
for Olig2 cells in the VZ, we isolated Olig2-GFP cells that
coexpressed CD15MMA or CD133 (Fig. 1E, Table 2), surface
markers expressed by CNS-SCs (24, 25). CD15MMA expres-
sion provided an additional 1.5-fold enrichment for VZ-
derived Olig2 cells (Figs. 6H and 7H). In addition, we selected
against the OP surface marker PDGFR (Figs. 6G and 7 G and
P–R). By using Olig2-GFP, anti-PDGFR, and CD15,0.4% of
E9.5 total spinal cord cells (Fig. 1E), and0.2% of E13.5 spinal
cord cells, were isolated (Fig. 7H). Immediately after sorting, the
isolated cells were positive for Sox2, nestin, and CD133 and
negative for NeuN (Table 2 and Fig. 6). Taken together, these
data indicate that Olig2 cells prospectively isolated from the
pMN domain express markers characteristic of CNS-SCs and
that these cells constitute the vast majority of VZ cells in the
pMN domain at E9.5 and E13.5. Therefore, Olig2 cells in the
pMN domain would appear to be good candidates for stem cells,
if such cells are, indeed, an abundant component of the VZ.
FACS-Isolated Suspensions of Murine MN Precursors Can Survive and
Differentiate After Direct Transplantation into Chick Embryonic Spinal
Cord. To examine the developmental potential of prospectively
isolated Olig2 cells, a suitable recipient for transplantation is
required. Because transplantation into the E9.5 murine spinal
cord is technically difficult, we used the E2 chick embryonic
spinal cord as a more accessible host (Fig. 1A). Transplanted
embryoid bodies derived from murine ES cells have been shown
to differentiate to MNs in this chick host (26). To determine
whether this system can also be used for transplantation of MN
precursor cells isolated directly from murine embryos by FACS,
we first transplanted cells expressing GFP from the Hb9 pro-
moter (26), which marks newly generated postmitotic MNs (27,
28). After incubation for 3 days to E5 (stage 27), mouse EGFP
(Hb9) neurons were observed in the ventral spinal cord, and
many of these neurons projected axons out of the ventral roots
(Fig. 1D). Thus, FACS-isolated murine MN precursors can
differentiate into neurons when transplanted into the E2 chick
spinal cord.
Prospectively Isolated E9.5 Olig2-GFP Cells Differentiate to bothMNs
and OPs After Direct Transplantation into Chick Embryonic Spinal
Cord. We next asked whether E9.5 Olig2-GFP progenitors can
differentiate to MNs in this transplantation assay. Because Olig2
expression is extinguished uponMNdifferentiation (20), to mark
the progeny of transplanted Olig2-GFP cells, we crossed
Fig. 1. (A) Schematic, illustrating experimental design. Murine-equivalent
isochronic (E9.5 Olig2 cells 3 chick E2 spinal cord) or heterochronic (E13.5
Olig2 cells3 chick E2 spinal cord) transplants are shown. Modified from ref.
45. (B Left) The pMN domain, marked by Olig2 expression (green), is bounded
dorsally by P2 (marked by Irx3, red) and ventrally by P3 (labeled by Nkx2.2,
blue) (46). (Middle) All nuclei labeled by DAPI (white). (Right) Virtually all
(99.9%) cells in pMN (DAPI, Irx3, and Nkx2.2) are Olig2. (C) FACS-
isolated Hb9-GFPNCAM cells from E9.5Hb9::EGFP embryonic mouse spinal
cord were transplanted into chick E2 spinal cord. Negative selection for NCAM
removed already-differentiated Hb9 MNs. (D) Transplanted Hb9-GFP cells
differentiate to MNs (open arrow) that project axons (labeled by anti-Tuj1
antibody, red, arrowheads) from the ventral root of the chick spinal cord. (E)
FACS plots of Olig2CD15PDGFR cells at E9.5. The PDGFR subpopu-
lation is not shown. (F) Location of murine E9.5 donor cells (-gal, green) and
quail carrier cells (QCPN, red) in chick spinal cord sectioned immediately after
transplantation. Transplanted E13.5 donor cells were located at similar posi-
tion (data not shown). Topro-3 (blue) stains all cell nuclei. (Scale bars, 100m.)
Table 1. Neuronal differentiation of transplanted Olig2 cells
Cells per one embryo E9.5 donor E13.5 donor
Hb9Cyn-1-gal cells 34  4 0
Hb9Cyn-1-gal cells 14  5 0
Total -gal cells 97  38* 108  20*
Three operated embryos were fixed after 3 days of incubation (at E5),
sectioned, and processed for triple labeling with anti-Hb9, anti-Cyn-1, and
anti--gal antibodies. Transplanted cells were counted on all serial sections
from each embryo. Data represent mean  SEM per one embryo.
*Difference not statistically significant (P  0.55).
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Olig2GFP/ mice to Rosa26 mice, which carry a ubiquitously
expressed lacZ transgene (29). For grafting, isolated Olig2,
PDGFR, CD15 cells were mixed with carrier cells isolated
from quail E2 ventral spinal cord (in a 1:4 ratio) and injected into
the lumen of E2 (stage 11–12) chick spinal cord (Fig. 1E). To
assess the number and distribution of transplanted cells, some
host embryos were fixed and analyzed 2 h after injection. Cells
expressing -galactosidase or QCPN (a quail cell nuclei-specific
antibody to mark quail carrier cells) were observed in the lumen
of the spinal cord (Fig. 1F). Serial sectioning and counting of
every section indicated that 120  48 murine cells were injected
per embryo (mean SEM, n  3 experiments).
Analysis at E5 (3 days posttransplantation) with two different
MN-specific nuclear markers, Hb9 (Fig. 2 A–B) and Isl12 (Fig.
2 C–D), revealed numerous -gal cells that coexpressed these
markers in the host spinal cord (Fig. 2 A and C). -gal cells
also coexpressed the panneuronal markers NeuN (Fig. 2 E–F)
and Cyn-1 (30) (see Fig. 8 A–C, which is published as supporting
information on the PNAS web site). Quantification of three
transplanted embryos sectioned in their entirety and triple-
labeled for -gal, Hb9, and Cyn-1 indicated that35% of -gal
cells expressed the MN-specific marker Hb9 (Table 1). Virtually
all of these Hb9 cells coexpressed Cyn-1 (Table 1). An addi-
tional 15% of the -gal cells were Cyn-1 and Hb9 (Table
1). Thus, 50% of surviving transplanted cells differentiated to
neurons, and 70% of these neurons expressed Hb9. The
remaining 30% of neurons may represent interneurons or classes
ofMNs that do not express Hb9 (30). Qualitatively similar results
were obtained in 37 chimeric embryos from 18 independent
experiments.
To investigate whether any E9.5 Olig2 cells differentiated to
glia, we incubated some transplanted embryos to E6, a stage
when chick oligodendrocyte differentiation begins (31). Close to
half of the -gal cells (40  8%, mean  SD of four sections
per embryo, n 2 embryos) expressed the OP marker PDGFR
(Fig. 4A–C Insets). Expression of GFAPwas not detected at this
stage (data not shown), consistent with the timing of astrocyte
differentiation in vivo. Thus, freshly isolated E9.5 Olig2-GFP
CD15PDGFR cells can generate both MNs and OPs after
in vivo transplantation.
E13.5 Olig2 Cells Generate Glia but Not Neurons After Transplanta-
tion into a Neurogenic Environment. Having established that mu-
rine E9.5 Olig2 cells transplanted into the chick spinal cord at
a murine-equivalent isochronic stage can differentiate to both
MNs and OPs, we next performed a heterochronic transplan-
tation experiment. We grafted isolated E13.5 Olig2-GFP,
PDGFR, CD15 cells (Fig. 7H) into chick hosts of the same
age as used for transplantation of E9.5 cells (Fig. 1A). Selection
against PDGFR cells was important at E13.5, because Olig2
is expressed by OPs at this stage (Fig. 7G and P–R). Quantifi-
cation of -gal cells 2 h after transplantation indicated that
107 18 E13.5 cells per embryo were injected. A similar number
of -gal cells was detected after 3 days of incubation (108  20
cells per embryo).
Strikingly, unlike the E9.5 Olig2 cells, transplanted E13.5
Olig2 cells did not generate any Hb9MNs (Fig. 3 A and C).
Furthermore, none of these cells expressed panneuronal mark-
ers, such as NeuN or Cyn-1 (Fig. 3E and Fig. 8D). Quantifi-
cation of all -gal cells on every section from each of three
embryos sectioned in toto confirmed this result (Table 1).
Qualitatively similar results were obtained in each of 29 chimeric
embryos from 15 independent experiments. By extrapolation,
therefore, not a single neuron was observed among 3,000
-gal cells (assuming 100 -gal cells per embryo). The
failure of these cells to differentiate to neurons was striking,
given their proximity to host cells expressing MN markers (Fig.
3 A, C, and E, and Fig. 8D, arrowheads).
Fig. 2. Transplanted, uncultured E9.5 Olig2CD15PDGFR cells express
MN-specific and panneuronal markers. (AA–DD) Triple labeling with anti--
gal antibody (green), Topro-3 (blue) and the indicated markers (red) shows that
transplanted murine donor cells (-gal, green) coexpress the MN markers Hb9.
(AA–BB’) and Isl12 (CC–DD) and the panneuronal marker NeuN (EE–F
F). Open arrowheads indicate coexpressing cells and white arrowheads indicate
-galmarker cells. The boxed regions in (A–F) are magnified in (A–F), respec-
tively. The nuclear marker Topro-3 (blue) is provided for reference in (B,D, and
F).Confirmationofcolabelingbyz-seriesanalysis is shownbelowandtotheright
of the images. D, dorsal region; V, ventral region. See Fig. 4 for analysis of glial
differentiation by E9.5 transplanted cells. (Scale bars, 100 m.)
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The robust neuronal differentiation obtained with E9.5 do-
nors (50% of transplanted cells), coupled with the fact that
similar numbers of E9.5 and E13.5 cells engrafted and survived
(Table 1), suggested that we should have been able to detect
neuronal differentiation by the transplanted E13.5 cells, even at
an incidence 10-fold below that of E9.5 cells. The fact that we
did not suggests that E13.5 Olig2 VZ-derived progenitors lack
the capacity to generate MNs or, indeed, any other class of
neurons in this permissive host environment. This behavior was
not due to the exclusion of CD15MMA cells from the
Olig2-GFP fraction, as similar results were obtained by using
Olig2-GFPPDGFR cells without additional surface marker
selection. In contrast to the lack of neuronal differentiation,
staining for glial markers revealed that a high proportion (70 
13%) of -gal cells expressed PDGFR (Fig. 4 D–F). In
addition, some -gal cells exhibited weak expression of the
astrocyte marker, GFAP (data not shown). These data suggest
that by E13.5, Olig2 cells possess glial, but not neuronal,
differentiation potential.
To determine whether the lack of neuronal differentiation by
transplanted E13.5 progenitors might reflect age-specific dam-
age suffered during the isolation procedure, we isolated and
transplanted E13.5 dorsal spinal cord VZ cells, which generate
dorsal interneurons at this stage (32), using the same dissociation
and sorting procedure, but selecting for Olig2-GFPCD15
cells. Many of these transplanted cells differentiated into neu-
rons expressing NeuN or Cyn-1 (see Fig. 9 A–D, which is
published as supporting information on the PNAS web site;
24.9 7.3% of -gal cells were Cyn-1 per section, mean SD.
of three sections per embryo, n  2 experiments) as well as into
glia (see Fig. 9 E–F). Therefore, the lack of neurogenesis by
transplanted E13.5 Olig2 cells does not reflect the inability of
progenitors in other regions of the VZ at E13.5 to differentiate
into neurons, after FACS-isolation and transplantation into
chick spinal cord. These control data provide further evidence
in support of the conclusion that Olig2 progenitors isolated
from E13.5 spinal cord are intrinsically restricted to glial fates.
Discussion
The idea that most neuroepithelial cells in the embryonic CNS
are multipotent, self-renewing stem cells in vivo has been
indirectly inferred from in vitro studies and from the expression
of various markers. But, to our knowledge, there are no data that
directly test this inference without the use of cell culture
manipulations. Retroviral lineage-tracing studies in the chick
spinal cord (33) have indicated that some MN progenitors are
multipotent, but such retrospective labeling experiments cannot
distinguish whether these progenitors underwent self-renewal or
rapidly generated separate lineages of committed neuronal and
nonneuronal precursors. Time-lapse imaging of cortical radial
glial cells in vivo has indicated that they divide asymmetrically,
to generate neuronal and radial glial progeny (reviewed in refs.
12 and 13), but these observations cannot resolve whether the
nonneuronal daughters of such divisions maintain the develop-
mental potentials available to the parent cell. The only case in
which self-renewal of embryonic neural progenitors has been
directly tested by prospective isolation and transplantation ex-
periments is in the peripheral nervous system, where progenitors
in the fetal sciatic nerve (34) or gut (35) have been shown to
retain multipotency (at the population level) for several days or
longer (36) after migration from the neural crest.
Here, we have addressed this question in the CNS, by pro-
spective isolation and transplantation of Olig2 cells from the
embryonic spinal cord. We find that transplanted Olig2 cells
isolated from E9.5 embryos readily generate MNs and cells that
express panneuronal but not MN markers, suggesting that the
host environment is permissive for the generation of multiple
classes of neurons. The E9.5 Olig2 cells also generate OPs. By
contrast, if these cells are isolated at E13.5 they generate glial
cells, but no neurons, in the same transplantation assay. Pro-
genitors isolated from dorsal regions of the E13.5 spinal cord,
Fig. 3. Transplanted, uncultured E13.5 Olig2CD15PDGFR cells do not
differentiate to neurons. Triple labeling with anti--gal antibody, Topro-3 (blue)
and neuronal markers (red) shows that transplanted murine donor cells (-gal,
green) do not coexpress either Hb9 (AA–BB) or Isl12 (CC–DD) or the
panneuronal markers NeuN (EE–FF). Arrowheads indicate -gal single-
positivecells. Theboxedregionsaremagnified in (A–F)withz-seriesviewstothe
right and below. D, dorsal region; V, ventral region. (Scale bar, 100 m.)
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when neurogenesis is ongoing in vivo (32), do generate neurons
in this assay, indicating that the failure of E13.5 Olig2 cells to
generate neurons is not a generic deficiency of all progenitors at
this stage.
Taken together, these data suggest that Olig2 cells at E13.5
are intrinsically restricted to a glial fate. Thus, the neurogenic
potential of the earlier Olig2 population is not maintained
during the switch to gliogenesis, implying that most Olig2 MN
progenitors do not self-renew in vivo and, therefore, are not stem
cells. Because Olig2 cells constitute 99.9% of the neuroepithe-
lial cells in pMN, then if multipotent, self-renewing progenitors
of MNs and OPs indeed exist in this domain (Fig. 5A), they must
be extremely rare. Alternatively, MNs andOPsmay be generated
by a common Olig2 progenitor that rapidly loses MN potential
(Fig. 5B) or by separate populations of committed Olig2 MN
and OP progenitors (Fig. 5C). In the first scenario (Fig. 5B),
individual Olig2 progenitors are initially multipotent (33), but
do not self-renew. In the second case (Fig. 5C), individual Olig2
cells may self-renew but are unipotent. In either case, Olig2
cells are not both multipotent and self-renewing in vivo, and,
thus, do not fit the accepted definition of a neural stem cell (2,
3, 37, 38). We cannot exclude that a small subpopulation of
Olig2 cells may be stem cells that escaped detection or failed to
engraft, in our cross-species assay. We also cannot exclude the
existence of very rare (0.1%) Olig2 stem cells in the pMN
domain. Either scenario, however, would still require a major
revision of the commonly (although not universally (2)) held
view that the majority of embryonic VZ cells are multipotent,
self-renewing stem cells (8, 10, 12–14).
The results obtained in the pMN domain could represent a
special case or could be generalizable to other regions of the
CNS. In the cortex, progenitors at late stages of neurogenesis
become intrinsically restricted to upper-laminar fates (39), sug-
gesting that they do not maintain the capacity to generate
(A–C Insets) Higher magnification details of -galPDGFR cells in the
smaller boxed region (A–C, open arrows). D, dorsal region; V, ventral region.
(Scale bar, 100 m.)
Fig. 4. Transplanted, uncultured E9.5 and E13.5 Olig2CD15PDGFR
cells generate glial cells. Triple labeling of chick embryos incubated to E5 or E6
with anti--gal antibody, Topro-3, and glial markers (red) show that some
(40%) murine E9.5 donor cells (-gal, green) weakly express the OP marker
PDGFR (AA–CC). A higher percentage (70%) of E13.5 donor cells
strongly express PDGFR (DD–FF). The anti-PDGFR antibody is murine-
specific and therefore does not detect endogenous chick OPs. Topro-3 (blue)
nuclear staining is shown for reference in (B and E). Open arrowheads,
coexpressing cells; arrowheads, -gal single-positive cells. The boxed re-
gions are magnified with z-series views to the right and below (A–F).
Fig. 5. Stem cell (A) and non-stem-cell (B and C)-based models for MN and
OP generation. PNG, PG, PN indicate progenitors with neuronal and glial, glial,
or neuronal potential, respectively. Circular arrows indicate self-renewal. SMN
and SOP indicate environmental signals for MN and OP differentiation, respec-
tively. Dashed arrowSMN in E13.5 indicates predicted behavior of E13.5
progenitors transplanted to an environment containing MN differentiation
signals. InB, individual progenitors may be bifatent (shown), or multipotential
but unifatent (not shown). Such cells may divide transitorily before losing MN
potential. Self-renewal of unipotent cells in model C is possible (dashed
circular arrow) but not obligatory.
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earlier-formed cortical neuron subtypes. By contrast, in the
forebrain subventricular zone and hippocampus, neurogenesis
persists into adulthood (reviewed in ref. 3), and, therefore, some
progenitor cells in these areas must maintain neurogenic capac-
ity (40). However these cases appear to represent the exception
rather than the rule (41, 42). The ability of embryonic CNS
progenitors to self-renew in vitro in serum-free medium con-
taining high concentrations of growth factors (5–7) may, there-
fore, represent the ‘‘capture’’ and propagation of a normally
transitory or very rare progenitor cell, analogous to the ability to
derive ‘‘embryonic stem cells’’ from primordial germ cells or
inner-cell mass cells in vitro (43, 44). Alternatively, such culture
conditions may induce multipotency and self-renewal in progen-
itors that do not behave as stem cells in vivo (15–17). The ability
to expand and differentiate neural stem cells in vitro is certainly
useful, but our results suggest that such cells are not represen-
tative of the majority of progenitor cells in the embryonic CNS
VZ in vivo.
Materials and Methods
Mice. Olig2GFP/mice were generated by homologous recombi-
nation in ES cells according to standard procedures. Character-
ization of Hb9::EGFP (26), and Rosa26 mice has been reported
in ref. (29).
In Vivo Transplantation of Single-Cell Suspensions. Fertile white eggs
were incubated to E2 (stage 15–17) and grafted as described in ref.
26. FACS-isolated murine cells were mixed with quail carrier cells
(1:4 ratio) and transplanted into E2 chick spinal cord in which a
small suction lesion had been created. Operated embryos were
incubated for an additional 3–4 days. Embryos were fixed in 4%
paraformaldehydePBS at 4°C and sectioned (10 m).
Supporting Information. Detail protocols of FACS isolation of
spinal cord neuroepithelial cells and immunohistochemistry are
available in Supporting Materials andMethods, which is published
as supporting information on the PNAS web site.
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